lifestyle.pluralist.com

Author: CSTONE PHARMACEUTICALS

CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

April 19, 2026
CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0

March 26, 2026
CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

March 26, 2026
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC

February 22, 2026
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

February 15, 2026